Flu Drugs May Reverse Cognitive Decline in HIV Patients

Scientists just found an unexpected ally in fighting cognitive decline among people with HIV: the same drugs we use to treat the flu.

Up to 24% of people living with HIV experience cognitive problems that interfere with daily tasks like concentrating at work or multitasking, even when their HIV medications are working perfectly. These issues have puzzled doctors for years, especially as more people with HIV are living longer, healthier lives.

Researchers at Northwestern University discovered that people with HIV lose protective sugar molecules called glycans faster than usual. These sugars normally keep inflammation in check throughout the body, but when they decline, chronic low-grade inflammation begins damaging the brain.

The team analyzed blood samples from over 100 people with HIV and found that those with cognitive impairment showed greater losses of two specific glycans. The connection was especially strong in women, possibly linked to menopause and estrogen levels.

Here's where it gets exciting. The researchers tested whether they could reverse this damage using existing flu medications. In mouse experiments, flu antivirals successfully restored the protective glycans and reduced inflammation.

Dr. Mohamed Abdel-Mohsen, the study's co-author, emphasized why this matters now more than ever. In 2022, more than half of people living with HIV in the U.S. were over 50 years old, and that number keeps growing. While HIV medications have dramatically extended lifespan, protecting quality of life remains crucial.

Why This Inspires

This research represents exactly the kind of progress that changes lives without requiring decades of drug development. The flu medications already exist, are already proven safe, and could potentially help millions of people maintain their cognitive sharpness as they age.

Dr. Alan Winston from Imperial College London, who wasn't involved in the study, called the work truly novel because it not only identifies the mechanism behind cognitive decline but also points toward an immediate solution. The study was published in the journal Med, opening the door for clinical trials in humans.

The discovery means people living with HIV might soon have tools to protect not just their lifespan but their health span too.